David Spencer, MD
Dermatology · Winston Salem, NCNPI 1134143605
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.3% of the total across 746 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations.
Across 746 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Sun Pharmaceutical Industries Inc.$1K
- Sanofi$1K
- Pfizer$1K
- Johnson & Johnson$855
- Regeneron Healthcare Solutions, Inc.$766
- plus $6K from 30 others
Across 3 payments — averaging $6655.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$20K
What the payments were for
- Speaking & faculty fees$1331%
- Food & beverage$13,52594%
- Education$6875%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 165 | $2,918 |
| Sun Pharmaceutical Industries Inc. | 54 | $1,414 |
| Sanofi | 52 | $1,279 |
| Pfizer | 68 | $1,250 |
| Johnson & Johnson | 36 | $855 |
| Regeneron Healthcare Solutions, Inc. | 30 | $766 |
| Novartis | 30 | $692 |
| Amgen | 38 | $665 |
| Lilly USA, LLC | 43 | $609 |
| E.r. Squibb & Sons, L.L.C. | 37 | $532 |
| LEO Pharma Inc. | 22 | $365 |
| Incyte Corporation | 14 | $349 |
| Mayne Pharma Commercial LLC | 22 | $335 |
| UCB, Inc. | 20 | $332 |
| Dermavant Sciences, Inc. | 11 | $230 |
| Medimetriks Pharmaceuticals, Inc. | 9 | $229 |
| Arcutis Biotherapeutics, Inc. | 15 | $224 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 11 | $208 |
| Almirall LLC | 7 | $148 |
| Galderma Laboratories, L.p. | 9 | $144 |
| Bristol Myers Squibb | 16 | $124 |
| EPI Health, LLC | 9 | $119 |
| Verrica Pharmaceuticals Inc. | 4 | $81 |
| Organon | 3 | $75 |
| Sandoz | 3 | $52 |
| Paratek Pharmaceuticals, Inc. | 3 | $49 |
| Merck | 3 | $47 |
| Biofrontera Inc. | 2 | $43 |
| Sebela Pharmaceuticals Inc. | 1 | $35 |
| Acelrx Pharmaceuticals, Inc. | 2 | $33 |
| Journey Medical Corporation | 2 | $33 |
| Convatec Inc. | 1 | $33 |
| Taro Pharmaceuticals USA, Inc. | 1 | $21 |
| Mimedx Group, Inc. | 1 | $21 |
| Botanix SB Inc | 1 | $21 |
| Dermira, Inc. | 1 | $15 |
How this compares
$14,345 in reported general payments places this provider in the 85th percentile of 475 dermatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 42 | $380,246 |
| CibinqoAbrocitinib | 12 | $67,151 |
| Dupixent SyringeDupilumab | 15 | $58,760 |
| OtezlaApremilast | 12 | $57,900 |
| Fluorouracil | 69 | $6,179 |
| Ammonium Lactate | 243 | $5,970 |
| Pimecrolimus | 13 | $5,966 |
| Ciclopirox | 83 | $3,583 |
| Ketoconazole | 241 | $3,249 |
| Tretinoin | 35 | $2,566 |
| Metronidazole | 50 | $2,348 |
| Calcipotriene | 20 | $2,327 |
| Clobetasol Propionate | 53 | $1,903 |
| Triamcinolone Acetonide | 126 | $1,711 |
| Desonide | 47 | $1,566 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerCibinqo | $1,250 | $67,15112 claims |
| AmgenOtezla | $665 | $57,90012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 475 dermatology providers in North Carolina.
Other dermatology in Winston Salem
- Steven FeldmanWinston Salem$3.4M
- Amy McMichaelWinston Salem$309K
- Joseph JorizzoWinston Salem$20K
- Nicole SeminaraHuntersville$1.4M
- Andrew LeeElkin$702K
- Christopher SayedChapel Hill$690K
- William HooverConcord$594K
- Patrick McElgunnCharlotte$565K
- George MagelHickory$554K
- Muneeb ShahClinton$451K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.